166 related articles for article (PubMed ID: 24098491)
1. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.
Krais JJ; De Crescenzo O; Harrison RG
PLoS One; 2013; 8(10):e76403. PubMed ID: 24098491
[TBL] [Abstract][Full Text] [Related]
2. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Guillen KP; Kurkjian C; Harrison RG
J Biomed Sci; 2014 Jul; 21(1):65. PubMed ID: 25047949
[TBL] [Abstract][Full Text] [Related]
3. Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Guillen KP; Restuccia A; Kurkjian C; Harrison RG
Pancreas; 2015 Aug; 44(6):945-52. PubMed ID: 25899647
[TBL] [Abstract][Full Text] [Related]
4. Annexin-directed β-glucuronidase for the targeted treatment of solid tumors.
Guillen KP; Ruben EA; Virani N; Harrison RG
Protein Eng Des Sel; 2017 Feb; 30(2):85-94. PubMed ID: 27986920
[TBL] [Abstract][Full Text] [Related]
5. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature.
Van Rite BD; Lazrak YA; Pagnon ML; Palwai NR; Neves LF; McFetridge PS; Harrison RG
Cancer Lett; 2011 Feb; 301(2):177-84. PubMed ID: 21194833
[TBL] [Abstract][Full Text] [Related]
6. Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Van Rite BD; Harrison RG
Cancer Lett; 2011 Aug; 307(1):53-61. PubMed ID: 21546157
[TBL] [Abstract][Full Text] [Related]
7. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide.
Krais JJ; Virani N; McKernan PH; Nguyen Q; Fung KM; Sikavitsas VI; Kurkjian C; Harrison RG
Mol Cancer Ther; 2017 Sep; 16(9):1855-1865. PubMed ID: 28522586
[TBL] [Abstract][Full Text] [Related]
8. Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.
Bennett EM; Anand R; Allan PW; Hassan AE; Hong JS; Levasseur DN; McPherson DT; Parker WB; Secrist JA; Sorscher EJ; Townes TM; Waud WR; Ealick SE
Chem Biol; 2003 Dec; 10(12):1173-81. PubMed ID: 14700625
[TBL] [Abstract][Full Text] [Related]
9. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
10. Structure of a mutant human purine nucleoside phosphorylase with the prodrug, 2-fluoro-2'-deoxyadenosine and the cytotoxic drug, 2-fluoroadenine.
Afshar S; Sawaya MR; Morrison SL
Protein Sci; 2009 May; 18(5):1107-14. PubMed ID: 19388075
[TBL] [Abstract][Full Text] [Related]
11. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.
Sorscher EJ; Hong JS; Allan PW; Waud WR; Parker WB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):321-9. PubMed ID: 22760227
[TBL] [Abstract][Full Text] [Related]
12. Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer.
Afshar S; Asai T; Morrison SL
Mol Cancer Ther; 2009 Jan; 8(1):185-93. PubMed ID: 19139128
[TBL] [Abstract][Full Text] [Related]
13. 6-Methylpurine derived sugar modified nucleosides: Synthesis and in vivo antitumor activity in D54 tumor expressing M64V-Escherichia coli purine nucleoside phosphorylase.
Hassan AEA; Abou-Elkhair RAI; Parker WB; Allan PW; Secrist JA
Eur J Med Chem; 2016 Jan; 108():616-622. PubMed ID: 26724729
[TBL] [Abstract][Full Text] [Related]
14. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
Singh PP; Joshi S; Russell PJ; Nair S; Khatri A
BMC Cancer; 2011 Aug; 11():368. PubMed ID: 21861932
[TBL] [Abstract][Full Text] [Related]
15. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors.
Lockett LJ; Molloy PL; Russell PJ; Both GW
Clin Cancer Res; 1997 Nov; 3(11):2075-80. PubMed ID: 9815599
[TBL] [Abstract][Full Text] [Related]
16. Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2'-deoxyriboside.
Deharvengt S; Wack S; Uhring M; Aprahamian M; Hajri A
Pancreas; 2004 Mar; 28(2):E54-64. PubMed ID: 15028961
[TBL] [Abstract][Full Text] [Related]
17. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
Martiniello-Wilks R; Wang XY; Voeks DJ; Dane A; Shaw JM; Mortensen E; Both GW; Russell PJ
J Gene Med; 2004 Dec; 6(12):1343-57. PubMed ID: 15493036
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
Virani NA; Thavathiru E; McKernan P; Moore K; Benbrook DM; Harrison RG
Cancer Lett; 2018 Jul; 425():174-182. PubMed ID: 29574275
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.
Wang XY; Martiniello-Wilks R; Shaw JM; Ho T; Coulston N; Cooke-Yarborough C; Molloy PL; Cameron F; Moghaddam M; Lockett TJ; Webster LK; Smith IK; Both GW; Russell PJ
Gene Ther; 2004 Nov; 11(21):1559-67. PubMed ID: 15343359
[TBL] [Abstract][Full Text] [Related]
20. The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology.
Mao C; Cook WJ; Zhou M; Koszalka GW; Krenitsky TA; Ealick SE
Structure; 1997 Oct; 5(10):1373-83. PubMed ID: 9351810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
